Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children's hospitals.

TitleMedication use in infants with severe bronchopulmonary dysplasia admitted to United States children's hospitals.
Publication TypeJournal Article
Year of Publication2019
AuthorsBamat NA, Kirpalani H, Feudtner C, Jensen EA, Laughon MM, Zhang H, Monk HM, Passarella M, Lorch SA
JournalJ Perinatol
Date Published2019 Jun 21
ISSN1476-5543
Abstract

OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD.

STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children's hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use.

RESULTS: In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17-45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (pā€‰<ā€‰0.0001), with a range of 22-50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD.

CONCLUSIONS: Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center.

DOI10.1038/s41372-019-0415-9
Alternate JournalJ Perinatol
PubMed ID31227785
Grant List2T32HD060550-06 / / U.S. Department of Health & Human Services | National Institutes of Health (NIH) /
K23HL136843 / / U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) /